Table 3.

Multivariable-adjusted association of biomarker levels and clinical outcomes in the placebo arm adjusted for clinical factors

	Adjusted Risk for CV Death or Heart Failure
			HR (95% CI) across quartiles				P value
Biomarker	HR (95% CI) per 1-SD of log- transformed biomarker values	P value	Q1	Q2	Q3	Q4	Multiple partial	Trend
MR-proANP	1.97 (1.58–2.46)	<0.001	Referent	1.60 (0.70–3.66)	2.72 (1.24–5.96)	4.35 (1.96–9.62)	<0.0001	<0.0001
MR-proADM	1.48 (1.27–1.73)	<0.001	Referent	1.90 (0.77–4.69)	2.45 (1.03–5.82)	5.51 (2.38–12.75)	<0.0001	<0.0001
CT-proET-1	1.47 (1.15–1.88)	0.002	Referent	2.03 (1.03–4.04)	0.99 (0.46–2.11)	2.73 (1.41–5.27)	<0.001	0.01
Copeptin	1.10 (0.91–1.33)	0.32	Referent	0.77 (0.37–1.57)	1.11 (0.66–1.86)	1.41 (0.87–2.28)	0.30	0.11

Covariates in model include standard clinical factors: age, sex, weight, history of hypertension, history of diabetes mellitus, current tobacco use, prior MI, prior PCI or CABG, systolic blood pressure, estimated GFR, ratio of apoB/apoA, LVEF, aspirin use, beta-blocker use, lipid-lowering medication use. Each biomarker analyzed separately in the placebo arm. In quartile analyses, “multiple partial” refers to a 3 degree of freedom test for the addition of all quartiles, “trend” refers to a 1 degree of freedom test for linear trend across quartiles.